Is there a high-risk subgroup of stage i epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?

Jamie N. Bakkum-Gamez, Debra L. Richardson, Leigh G. Seamon, Giovanni D. Aletti, Cecelia A. Powless, Gary L. Keeney, David M. O'Malley, William A. Cliby

Research output: Contribution to journalArticlepeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)1125-1131
Number of pages7
JournalInternational Journal of Gynecological Cancer
Issue number7
StatePublished - Oct 2010


  • Carboplatin
  • Chemotherapy
  • Death from disease
  • Disease recurrence
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this